

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

UPDATE ON QUALIFICATION OF THE JOINT COMPANY SECRETARY

References are made to the announcement of the Company dated September 5, 2022 in relation to, among others, the waiver granted to the Company by The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) from strict compliance with Rules 3.28 and 8.17 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) regarding the eligibility of Mr. Quanwei Yuan (“**Mr. Yuan**”) to act as a company secretary of the Company (the “**Company Secretary**”) for a period from September 5, 2022 to July 4, 2024 (the “**Waiver Period**”).

The Company hereby announces that on November 27, 2024, the Company has obtained a confirmation from the Stock Exchange that, upon the expiry of the Waiver Period, Mr. Yuan has acquired the relevant experience within the meaning of Note 2 to Rule 3.28 of the Listing Rules, and is capable of discharging the functions as the Company Secretary independently (the “**Qualification**”) and a further waiver is no longer necessary. The Company will continue to retain the arrangement of joint Company Secretaries under which Ms. Kwan Sau In, the current joint Company Secretary, will continue to assist Mr. Yuan in performing his duties.

In July 2024, the Company underwent personnel changes, which resulted in a temporary shortage of staff responsible for corporate governance matters and the increased workload for the remaining team led by Mr. Yuan. Such additional workload significantly strained the already limited resources, affecting the overall efficiency of corporate governance processes. As a result, there was an inadvertent delay (the “**Delay**”) in seeking confirmation from the Stock Exchange regarding the eligibility of Mr. Yuan to act as the Company Secretary pursuant to Rule 3.28 of the Listing Rules, during which time Mr. Yuan continued to be assisted by Ms. Kwan Sau In. From the expiry of the Waiver Period to November 26, 2024, Mr. Yuan’s Qualification had not been confirmed or waived by the Stock Exchange, during which the role of Mr. Yuan as a joint Company Secretary did not fully satisfy the

requirement under Rule 3.28 of the Listing Rules. However, the Company believes the Delay has no bearing on Mr. Yuan's Qualification as (i) the primary cause of the Delay has been resolved with the recruitment of new staff members who have been provided with comprehensive training on corporate governance and Listing Rules requirements; (ii) a staff coordination mechanism has been established to ensure that responsibilities are swiftly and effectively reassigned, enabling timely distribution and completion of corporate governance tasks without disruption; and (iii) Mr. Yuan's extensive experience and continuous training would enable the Company to further strengthen its corporate governance capabilities, ensure adherence to good corporate governance practices and enhance its operational efficiency.

By order of the Board
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, December 3, 2024

As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Mr. Stephen Hui Wang, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Ms. Yun Qiu and Dr. Xiang Qian as independent non-executive Directors.